Disease Burden and Challenges of Chronic Kidney Disease in North and East Asia
Jinwei Wang,Luxia Zhang,Sydney C.W. Tang,Naoki Kashihara,Yong Soo Kim,Ariunaa Togtokh,Chih‐Wei Yang,Minghui Zhao
DOI: https://doi.org/10.1016/j.kint.2017.12.022
IF: 19.6
2018-01-01
Kidney International
Abstract:North and East Asia includes mainland China (including Hong Kong), Japan, Mongolia, North Korea, South Korea, and Taiwan (Figure 1). The region comprises a population of more than 1.6 billion, with considerable diversities in economy, living habits, climates, and environments. North Korea is classified as a low-income country by World Bank criteria, whereas China and Mongolia belong to the upper middle income group, and Japan, Hong Kong, South Korea, and Taiwan to the high-income group with highly developed economies. Therefore, the burden and spectrum of chronic kidney disease (CKD), as well as strategies to prevent and manage the disease, should be highly diverse. CKD is common in the region. The prevalence among the general adult population was 10.8% in mainland China, 11.9% in Taiwan, 12.9% in Japan, 13.7% in South Korea, and 13.9% in Mongolia.1Jha V. Garcia-Garcia G. Iseki K. et al.Chronic kidney disease: global dimension and perspectives.Lancet. 2013; 382: 260-272Google Scholar, 2Zhang L. Wang F. Wang L. et al.Prevalence of chronic kidney disease in China: a cross-sectional survey.Lancet. 2012; 379: 815-822Google Scholar So far, North Korea has no formal data reported on CKD prevalence. Although the total prevalence is equivalent, Taiwan, Japan, and South Korea reported a much higher prevalence of reduced estimated glomerular filtration rate (typically >5%) than that in China (only 1.7% in a national survey).1Jha V. Garcia-Garcia G. Iseki K. et al.Chronic kidney disease: global dimension and perspectives.Lancet. 2013; 382: 260-272Google Scholar This indicates that a large proportion of CKD patients in China is in the early stages with proteinuria as a sole indicator. Regarding the incidence and prevalence of treated end-stage kidney disease (ESKD), Taiwan has the highest numbers around the world, which was 455.0 per million population (pmp)/yr and 3219.4 pmp in 2014, according to the statistics released by the United States Renal Data System.3United States Renal Data System. The 2016 USRDS Annual Data Report reference tables. Available at: https://www.usrds.org/reference.aspx. Accessed September 3, 2017.Google Scholar The corresponding figures in Japan and South Korea were 284.6 pmp/yr and 2504.8 pmp, 256.0 pmp/yr and 1571.5 pmp, respectively. Nearly one-half of the ESKD cases were attributed to diabetes.3United States Renal Data System. The 2016 USRDS Annual Data Report reference tables. Available at: https://www.usrds.org/reference.aspx. Accessed September 3, 2017.Google Scholar China reported a much lower burden of ESKD, with an incidence and prevalence of dialysis at 15.4 pmp/yr and 237.3 pmp, respectively, in 2011. However, the corresponding rates were higher in big cities. The incidence and prevalence were 107.3 pmp/yr and 524.6 pmp in Beijing and 82.9 pmp/yr and 544.7 pmp in Shanghai in 2011.4Liyanage T. Ninomiya T. Jha V. et al.Worldwide access to treatment for end-stage kidney disease: a systematic review.Lancet. 2015; 385: 1975-1982Scopus (763) Google Scholar From 2001/2002 to 2013/2014, the prevalence of ESKD increased by 48.2%, 85.0%, and 124.4% in Japan, Taiwan, and South Korea, respectively. One of the reasons for this significant rise in ESKD prevalence was aging; the elderly population (65 years or above) not only constituted the largest proportion of ESKD cases (around 80% in both Japan and Taiwan), but this population also continued to increase in incident ESKD during the past decade.3United States Renal Data System. The 2016 USRDS Annual Data Report reference tables. Available at: https://www.usrds.org/reference.aspx. Accessed September 3, 2017.Google Scholar The large number of patients with ESKD will impose a huge economic burden on the society as they inevitably incur high medical expenses through renal replacement therapy (RRT) (Table 1).Table 1Chronic kidney disease epidemics in North and East AsiaParametersChinese mainlandJapanMongoliaSouth KoreaTaiwanPrevalence of CKD,1Jha V. Garcia-Garcia G. Iseki K. et al.Chronic kidney disease: global dimension and perspectives.Lancet. 2013; 382: 260-272Google Scholar %10.8012.9013.9013.7aThe data was based on survey of urban population.11.90Prevalence of CKD stages,1Jha V. Garcia-Garcia G. Iseki K. et al.Chronic kidney disease: global dimension and perspectives.Lancet. 2013; 382: 260-272Google Scholar, 6Xu X. Wang G. Chen N. et al.Long-term exposure to air pollution and increased risk of membranous nephropathy in China.J Am Soc Nephrol. 2016; 27: 3739-3746Google Scholar % 15.700.60—2.001.02 23.401.70—6.703.79 3 (a and b)1.6010.408.404.806.81 40.100.201.100.200.22 50.030.200.200.040.10Incidence of treated ESKD3United States Renal Data System. The 2016 USRDS Annual Data Report reference tables. Available at: https://www.usrds.org/reference.aspx. Accessed September 3, 2017.Google Scholar15.4 pmp/yrbThe incidence of treated ESKD of China is much higher in big cities (e.g., 107.3 pmp/yr in Beijing and 82.9 pmp/yr in Shanghai).284.6 pmp226.6 pmp256.0 pmp455.0 pmpPrevalence of ESKD3United States Renal Data System. The 2016 USRDS Annual Data Report reference tables. Available at: https://www.usrds.org/reference.aspx. Accessed September 3, 2017.Google Scholar237.3 pmpcThe prevalence of ESKD of China is much higher in big cities (e.g., 524.6 pmp in Beijing and 544.7 pmp in Shanghai).2504.8 pmp—1571.5 pmp3219.4 pmpPrevalence of diabetes,3United States Renal Data System. The 2016 USRDS Annual Data Report reference tables. Available at: https://www.usrds.org/reference.aspx. Accessed September 3, 2017.Google Scholar %9.407.7056.30—Prevalence of hypertension,3United States Renal Data System. The 2016 USRDS Annual Data Report reference tables. Available at: https://www.usrds.org/reference.aspx. Accessed September 3, 2017.Google Scholar %38.2043.904530.60—Prevalence of nephrologists,9Bello A.K. Levin A. Tonelli M. et al.Assessment of global kidney health care status.JAMA. 2017; 317: 1864-1881Google Scholar %5.1–10 pmp>15 pmp>15 pmp>15 pmp>15 pmpCKD, chronic kidney disease; ESKD, end-stage kidney disease; pmp, per million population.a The data was based on survey of urban population.b The incidence of treated ESKD of China is much higher in big cities (e.g., 107.3 pmp/yr in Beijing and 82.9 pmp/yr in Shanghai).c The prevalence of ESKD of China is much higher in big cities (e.g., 524.6 pmp in Beijing and 544.7 pmp in Shanghai). Open table in a new tab CKD, chronic kidney disease; ESKD, end-stage kidney disease; pmp, per million population. Diabetes mellitus and hypertension are the leading causes of CKD worldwide. In North and East Asia, the same pattern is observed in high-income countries, while the spectrum of CKD and ESRD in middle-income countries is still undergoing transition. In the past 3 decades, China witnessed an economic boom, and it is speculated that a high dietary caloric intake and a sedentary lifestyle led to a considerable increase in metabolic diseases. Since the surge in the prevalence of hypertension and diabetes in the 1990s, metabolic diseases may eventually take over glomerulonephritis as the main cause of CKD and ESKD in China. Based on a national in-patient database of China, it was found that the proportion of hospital discharges from CKD due to diabetes mellitus had surpassed that from glomerulonephritis since 2010, and that the magnitude of this gap was more significant in urban cities than in rural areas.5Zhang L. Long J. Jiang W. et al.Trends in chronic kidney disease in China.N Engl J Med. 2016; 375: 905-906Scopus (207) Google Scholar Regarding the etiology of glomerulonephritis, the disease spectrum is also changing. Based on an 11-year (2004–2014) renal biopsy series with 71,151 native biopsies in 283 cities in China, Xu et al.6Xu X. Wang G. Chen N. et al.Long-term exposure to air pollution and increased risk of membranous nephropathy in China.J Am Soc Nephrol. 2016; 27: 3739-3746Google Scholar found that the frequency of membranous nephropathy increased by 13% annually and that the risk of the disease was associated with long-term exposure to high levels of fine particulate matter of <2.5 μm, which is the primary composite of air pollution identified in China. Another important reason for the heightening of CKD in North and East Asia is the wide use of certain potentially toxic traditional herbal medicines. The now well-known nephrotoxin, aristolochic acid (AA), is contained in some commonly used traditional herbal products. According to the China National Survey of CKD, the prevalence of self-reported long-term intake of AA-containing herbal medicine was 1.5%.2Zhang L. Wang F. Wang L. et al.Prevalence of chronic kidney disease in China: a cross-sectional survey.Lancet. 2012; 379: 815-822Google Scholar Although few incidence or prevalence investigations had been conducted in the region, the disease burden of AA-associated nephropathy could be huge in the setting of ubiquitous use of herbal medicines in the past. However, after the official banning of AA-containing herbal medicine in China, AA-associated nephropathy cases decreased significantly though detailed data are lacking. Another cause of drug-induced CKD is the abuse of nonsteroidal anti-inflammatory drugs (NSAIDs), which could be easily accessed in China. NSAIDs are commonly used to relieve labor-associated chronic tiredness or used as a painkiller, which may lead to addiction, especially in rural areas of China. Long-term exposure to NSAIDs induces chronic interstitial nephritis and is an important cause of CKD in China. The national survey of CKD in China showed the estimated prevalence of regular use of NSAIDs to be 3.6%.2Zhang L. Wang F. Wang L. et al.Prevalence of chronic kidney disease in China: a cross-sectional survey.Lancet. 2012; 379: 815-822Google Scholar Acute kidney injury (AKI) is another important cause of CKD. The incidence and spectrum of AKI varies among countries/regions within North and East Asia. In Japan, the incidence of AKI among the hospitalized population is 6.9%.7Yang L. Acute kidney injury in Asia.Kidney Dis (Basel). 2016; 2: 95-102Google Scholar In China, the national survey of AKI showed a detection rate of only 1% in academic/local hospitals using Kidney Disease: Improving Global Outcomes (KDIGO) criteria and 2% by expanded criteria (change of 50% in serum creatinine during hospital stay).8Yang L. Xing G. Wang L. et al.Acute kidney injury in China: a cross-sectional survey.Lancet. 2015; 386: 1465-1471Google Scholar The disparity between the 2 countries could be attributable to the insufficient monitoring of renal function in China, which was only evident among 25% of patients in the China national survey of AKI, compared with 69% in Japan.7Yang L. Acute kidney injury in Asia.Kidney Dis (Basel). 2016; 2: 95-102Google Scholar The early diagnosis of AKI and renal referral are still suboptimal in China, which might subsequently become an important source of CKD.8Yang L. Xing G. Wang L. et al.Acute kidney injury in China: a cross-sectional survey.Lancet. 2015; 386: 1465-1471Google Scholar Both high-income and middle-income countries in North and East Asia face the challenge of an increasing burden of CKD. On the one hand, the aging population will steadily increase the background of susceptible population that will develop CKD and ESKD in all countries/regions. On the other hand, the transition from glomerulonephritis to metabolic disease-related CKD, as well as a large number of patients with early stage CKD imply an emerging source of subjects who could potentially progress to advanced CKD stages. Taken together, these will impose an enormous pressure on the health system in middle-income countries, especially in China, which has the largest population in the world. Composite measures should be taken to improve the competency in detection, prevention, and management of CKD, as well as the access to RRT among ESKD patients. CKD has been considered as a risk amplifier of all noncommunicable diseases. However, measurement of serum creatinine with a report of estimated glomerular filtration rate and urine proteinuria/albuminuria was usually available only in secondary/tertiary hospitals and rarely available in primary health care settings around the countries/regions in North and East Asia,9Bello A.K. Levin A. Tonelli M. et al.Assessment of global kidney health care status.JAMA. 2017; 317: 1864-1881Google Scholar which will limit the ability for early detection of CKD. Furthermore, there is no explicit policy or preventive action available for the control of the CKD epidemic. As there are well-established prevention protocols for other common noncommunicable diseases, such as cardiovascular diseases and cancer, the inclusion of measurement of indicators of CKD into the surveillance system of cardiovascular diseases will probably benefit efforts in the prevention and control of CKD. Regarding ESKD, it is speculated that the worldwide prevalence of RRT will double by 2030, with the fastest growth in Asia.4Liyanage T. Ninomiya T. Jha V. et al.Worldwide access to treatment for end-stage kidney disease: a systematic review.Lancet. 2015; 385: 1975-1982Scopus (763) Google Scholar In North and East Asia, comprehensive renal registry systems and universal access to RRT have already been achieved in high-income countries. However, in middle-income countries of the region, the coverage and quality of the dialysis registries still need to be improved. As a road map to improve access to RRT, it is essential to establish an effective registry with mandatory and accurate collection of individual dialysis and/or transplantation data. The advent of the digital age may facilitate the process of establishing a robust registry by linking to the medical claims or health insurance database. In China, another barrier for universal access to RRT is the urban-rural inequity in health care. For example, most of the dialysis centers are located in cities, especially big cities. Patients from rural areas will pay a higher price in terms of traveling time and money to access health care. Although the government has expanded the health insurance system, known as the New Rural Co-operative Medical Care System, to mitigate the funding barrier for people living in rural villages to get access to health care, universal access to RRT may still require further improvements in terms of reimbursement policy, sustainable funding, infrastructure construction, and workforce training. All the authors declared no competing interests. The authors gratefully acknowledge the detailed review and helpful comments provided by David Harris. Trends in end-stage kidney disease in Shanghai, ChinaKidney InternationalVol. 95Issue 1PreviewWe read with interest the review by Wang et al. on the burden of chronic kidney disease in North and East Asia.1 Full-Text PDF Open ArchiveThe authors replyKidney InternationalVol. 95Issue 1PreviewWe thank Zijin Chen and colleagues for their letter discussing the incidence and prevalence trends in end-stage kidney disease (ESKD) in Shanghai, China, between 2007 and 2015.1 Their analysis is based on a local registry system including all dialysis centers and updates a recently published review we referenced on the disease burden of chronic kidney disease in North and East Asia.2 However, these data may be restricted to registered residents. Immigrant workers who were not covered by health insurance might not have been included. Full-Text PDF Open Archive